This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Tazoral
Description: Tazarotene is a orally active formulation of Tazorac gel or cream. Tazarotene binds to, and activates Retinoic acid receptors (RARs).
Actavis and Allergan
In November 2014, Actavis and Allergan announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transaction is valued at approximately $66 billion, or $219 per Allergan share.
In March 2015, Actavis announced that it has completed the acquisition of Allergan in a cash and equity transaction valued at approximately $70.5 billion.
In June 2015, Actavis announced that the company has adopted Allergan as its new global name and will begin trading under a new symbol (AGN). The company name change follows the acquisition of Allergan in March 2015 and the approval of the name change by Actavis shareholders in June 2015.
Pfizer and Allergan
In November 2015, Pfizer and Allergan announced that their boards of...See full deal structure in Biomedtracker
Oral Tazarotene News
Pink Sheet Seasonale Lo filing by June 30
Pink Sheet Allergan Tazoral regulatory update
Additional information available to subscribers only: